AstraZeneca and Oracle sign term sheet for AI-driven patient recruitment

AstraZeneca and Oracle have signed a non-binding term sheet to collaborate on using artificial intelligence for healthcare applications. The two companies announced the agreement, which focuses on leveraging real patient health data to identify and recruit individuals for drug trials more efficiently. This partnership adds to the growing number of collaborations between pharmaceutical manufacturers and technology firms in the health sector.

The deal is not yet final, as the parties have only exchanged a term sheet. Neither AstraZeneca nor Oracle disclosed the financial value of the agreement or confirmed specific monetary terms. According to The Next Web, the arrangement allows both firms to outline their intentions before finalizing the contract details. The collaboration combines AstraZeneca’s expertise in drug science, clinical trials, and regulatory compliance with Oracle’s cloud infrastructure, AI tools, and anonymized patient data from hospitals.

Context and Background

Recruiting participants remains one of the most time-consuming phases in developing new medications. When clinical trials enroll patients slowly, the studies take longer to complete and incur higher costs. The firms aim to help physicians identify eligible candidates for studies sooner, thereby reducing delays. Additionally, they plan to utilize the aggregated data to detect diseases at earlier stages and monitor the safety of drugs after they reach the market.

Pascal Soriot, AstraZeneca’s chief executive, stated that the collaboration brings together leaders in healthcare and AI on a global scale. The initiative is designed to operate at a large scale, utilizing Oracle’s health unit capabilities to process vast amounts of information. This approach seeks to streamline the traditionally bottlenecked process of trial enrollment while maintaining rigorous scientific standards throughout the development lifecycle.

Who is Affected

The first program under this agreement will operate in Abu Dhabi in partnership with M42, a healthcare company based in the United Arab Emirates. Doctors in this initial phase will focus on identifying individuals whose high blood pressure is not under control. According to AstraZeneca, these patients will be treated according to established guidelines, and more of them will subsequently be signed up for clinical trials. This pilot serves as a test case for the broader global rollout planned by the two companies.

Future projects are scheduled to expand into the United States, the Middle East, and Europe. These subsequent initiatives will cover a wider range of medical conditions, including cancer, heart and kidney disease, lung and immune conditions, and rare diseases. AstraZeneca emphasized that it will not have access to the identities of the patients involved. Each project must pass legal, privacy, and ethics checks before proceeding, ensuring that patient data remains protected and anonymized throughout the process.

What should you do?

Security and technology professionals should monitor how pharmaceutical and tech firms handle sensitive health data in AI collaborations. Organizations involved in similar partnerships should ensure robust data anonymization protocols are in place before sharing patient information. It is also important to verify that all data processing complies with regional privacy regulations and ethical standards.

What to do and how to stay safe: AstraZeneca

• Review data sharing agreements to ensure patient identities are fully anonymized before any AI processing occurs.
• Verify that third-party partners have undergone independent security and privacy audits prior to accessing health data.
• Monitor for updates on the finalization of the term sheet and any disclosed security frameworks for the collaboration.
• Ensure that clinical trial data handling complies with local privacy laws in the US, Europe, and the Middle East.

Step-by-step guide: Prompt Injection Warning Signs: How to Spot AI Manipulation

General security guidance from the Threat Times newsroom. It is not confirmed advice from the organisations named in this story.

Frequently asked questions

How much money is involved in the AstraZeneca and Oracle deal?

Neither firm has disclosed or confirmed the financial value of the agreement, as they have only signed a non-binding term sheet.

What is the first project under this partnership?

The initial program will run in Abu Dhabi with M42, focusing on patients with uncontrolled high blood pressure.

Will AstraZeneca see the names of the patients?

No, AstraZeneca stated it will not see who the patients are, as the data from hospitals will have names removed.